41st week of 2013 patent applcation highlights part 33 |
Patent application number | Title | Published |
20130266553 | Albumin Fusion Proteins - The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention. | 2013-10-10 |
20130266554 | Lysozymes - The present invention is directed to lysozyme variants and nucleotide sequences encoding same. The lysozyme variants have antimicrobial and/or lysozyme activity and comprise an alteration of an amino acid sequence at one or more positions. The present invention is also directed to methods for producing and of using the | 2013-10-10 |
20130266555 | THERAPEUTIC AGENT FOR DISC HERNIATION - The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk. | 2013-10-10 |
20130266556 | PROCESSING BIOMASS - Biomass (e.g., plant biomass, animal biomass, microbial, and municipal waste biomass) is processed to produce useful products, such as food products and amino acids. | 2013-10-10 |
20130266557 | METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) - Methods and formulations for treating a sarcoma in humans using an epimetabolic shifter, such as Coenzyme Q10, a building block of CoQ10, a derivative of CoQ10, an analog of CoQ10, a metabolite of CoQ10, or an intermediate of the coenzyme biosynthesis pathway, are described. Methods for assessing the efficacy of treatment of, diagnosing, and prognosing sarcoma are also provided. | 2013-10-10 |
20130266558 | Humanized Anti-CD22 Antibodies And Their Use In Treatment Of Oncology, Transplantation And Autoimmune Disease - Provided herein are chimeric and humanized versions of anti-CD22 mouse monoclonal antibody, HB22.7, which comprise human or humanized framework regions of the immunoglobulin heavy chain variable region (“VH”) and light chain variable region (“VK”). The FW regions may contain one or more backmutations in which a human FW residue is exchanged for the corresponding residue present in the parental mouse heavy or light chain. The human or humanized VH framework regions may comprise one or more of the following residues: a valine at position 24 of FW1, a glycine at position 49 of FW2, and an asparagine at position 73 of FW3, numbered according to Kabat. Further provided are pharmaceutical and immunotherapeutic compositions, and methods using anti-CD22 antibodies that preferably mediate human ADCC, CDC, and/or apoptosis for: the treatment of B cell diseases in humans, including B cell malignancies, autoimmune disease, GVHD, humoral rejection, and post-transplantation lymphoproliferative disorder. | 2013-10-10 |
20130266559 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 2013-10-10 |
20130266560 | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation - In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier. | 2013-10-10 |
20130266561 | B-CELL REDUCTION USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES - The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules. | 2013-10-10 |
20130266562 | VARIABLE REGION SEQUENCES OF IL-31 MONOCLONAL ANTIBODIES AND METHODS OF USE - Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human IL-31. CDR regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein V | 2013-10-10 |
20130266563 | SUBSTITUTED 4-(SELENOPHEN-2(OR-3)-YLAMINO)PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF - Selenophene compounds of formula (I) are described herein. In the compounds of Formula (I), ring A is a 6-membered aromatic fused ring, optionally containing one, two or three nitrogen atoms; a 5-membered heteroaromatic fused ring; or a mono- or bicyclic saturated heterocyclic fused ring having at least one ring member selected from the group consisting of N, O, S, SO and SO | 2013-10-10 |
20130266564 | ANTIBODIES SELECTIVE FOR CELLS PRESENTING ErbB2 AT HIGH DENSITY - An erbB2 antibody is provided that binds preferentially to disease cells having an erbB2 density greater than a normal erbB2 density. The erbB2 antibody comprises a heavy chain and a light chain. Each chain has a constant region and a variable region. Each variable region comprises framework regions and complementarity determining regions (CDRs), wherein the CDRs have an amino acid sequence set forth below: For the heavy chain: CDR1 GFNIKDTYIH (SEQ ID No. 1) CDR2 RIYPTNGY | 2013-10-10 |
20130266565 | ANTI-MHC ANTIBODY ANTI VIRAL CYTOKINE FUSION PROTEIN - The invention provides a fusion protein comprising an antibody that binds to a human major histocompatibility complex presenting a peptidic fragment of a hepatitis-B-virus protein and an anti-viral cytokine and methods of using the same. | 2013-10-10 |
20130266566 | METHODS OF INHIBITING FIBROSIS USING ANTI-PAI-1 ANTIBODIES - Provided are anti-PAI-1 antibodies or antibody fragments and methods of using them. | 2013-10-10 |
20130266567 | ANTI-SERUM ALBUMIN BINDING SINGLE VARIABLE DOMAINS - The invention relates to improved anti-serum albumin immunoglobulin single variable domains, as well as ligands and drug conjugates comprising such variable domains, compositions, nucleic acids, vectors and hosts. | 2013-10-10 |
20130266568 | ACTIVATABLE BISPECIFIC ANTIBODIES - The current invention relates to bispecific antibodies wherein the binding affinity to one of the two antigens is reduced and which can be activated by tumor- or inflammation-specific proteases, and the preparation and use of such bispecific antibodies. | 2013-10-10 |
20130266569 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CANCER - An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody. | 2013-10-10 |
20130266570 | Targeting Intracellular Target-binding Determinants with Intracellular Antibodies - The invention provides a method for inhibiting an intracellular target in a cell with a bispecific antibody comprising contacting the cell with a bispecific antibody having a first Fv fragment with a cell-penetrating determinant and a second Fv fragment with an intracellular target-binding determinant under suitable conditions so that the first Fv fragment causes the bispecific antibody to enter the cell and the second Fv fragment binds the intracellular target in the cell and thereby inhibiting the intracellular target. | 2013-10-10 |
20130266571 | THREE-DIMENSIONAL STRUCTURE OF COMPLEMENT RECEPTOR TYPE 2 AND USES THEREOF - Disclosed is a crystalline human CR2 protein in complex with C3d, and the three dimensional structure of the crystalline complex. Also disclosed are methods of use of the structure, particularly for structure-based identification of compounds that bind to CR2 and inhibit or enhance the binding of CR2 to a natural ligand, that bind to CR2 and agonize or antagonize the receptor, that bind to CR2 and inhibit or enhance CR2 dimerization, or that use the C3-binding ability of CR2 as a drug delivery vehicle. Also disclosed are therapeutic compounds obtained by such methods and uses for such compounds. | 2013-10-10 |
20130266572 | NUCLEIC ACIDS TARGETING TCTP FOR USE IN THE TREATMENT OF CHEMO-OR HORMONE- RESISTANT CANCERS - The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer. | 2013-10-10 |
20130266573 | Specific binding proteins and uses thereof - The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806. | 2013-10-10 |
20130266574 | HUMAN ANTIBODIES TO HUMAN ANGIOPOIETIN-LIKE PROTEIN 4 - A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human angiopoietin-like protein 4 (hANGPTL4) is provided. The human anti-hANGPTL4 antibodies are useful in treating diseases or disorders associated with ANGPTL4, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL4 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like. | 2013-10-10 |
20130266575 | OprF/I AGENTS AND USE THEREOF IN HOSPITALIZED AND OTHER PATIENTS - The present invention relates to a new use of a vaccine comprising a fusion protein that comprises the | 2013-10-10 |
20130266576 | THERAPEUTIC FACTOR VIII ANTIBODIES - The present invention relates to therapeutic FVIII antibodies. In particular, the present invention relates to FVIII antibodies having the ability to prolong the circulatory half life of FVIII. The present invention furthermore relates to use of such antibodies in treatment and prophylaxis of haemophilia A. | 2013-10-10 |
20130266577 | USE OF A CD28 BINDING SUBSTANCE FOR MAKING A PHARMACEUTICAL COMPOSITION - The invention relates to the use of a CD28-specific superagonistic monoclonal antibody (mAb) or of a mimicry compound hereto for making a pharmaceutical composition for the induction and/or multiplication of regulatory T cells. | 2013-10-10 |
20130266578 | METHODS OF TREATING AN OVERWEIGHT SUBJECT - The invention generally relates in part to methods of effecting weight loss and/or improving glucose tolerance in a patient in need thereof, comprising administering a MetAP2 inhibitor. | 2013-10-10 |
20130266579 | Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof - Provided herein are modified anti-EGFR antibodies and nucleic acid molecules encoding modified anti-EGFR antibodies. Also provided are methods of treatment and uses using modified anti-EGFR antibodies. | 2013-10-10 |
20130266580 | Methods and Compositions for Using Insulin-Like Growth Factor Binding Protein 6 in Treating and Diagnosing Diabetes - Methods and compositions for treating, detecting, diagnosing or assisting in the diagnosis of diabetes or diabetes-related complications are provided. Insulin-growth factor binding protein 6 (IGFBP6) has been determined to be a biomarker for type 1 diabetes (T1D) as well as for certain T1D complications such as nephropathy, retinopathy, and blindness. Compositions that prevent expression of IGFBP6 or block binding of IGFBP6 with its target, insulin-growth factor II (IGF-II), can be used to treat one or more symptoms or pathological processes of diabetes. Assaying for levels of IGFBP6 can be used to monitor disease progression, determine disease severity, and determine risk of developing diabetes or diabetes-related complications. | 2013-10-10 |
20130266581 | ANTI-VEGF ANTIBODIES - Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in research, diagnostic and therapeutic applications. | 2013-10-10 |
20130266582 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND NEURODEGENERATIVE DISEASES - The present invention relates to compositions and methods for regulating ROC-mediated death-associated protein kinase (DAPk) activity. The compositions and methods of the present invention are useful for treating or ameliorating cancer as well as pathologies associated with neuronal cell death, such as epilepsy and hypoxia/ischemia acute brain injury. The present invention further relates to screening methods for identifying agents that regulate ROC-mediated DAPk activation. | 2013-10-10 |
20130266583 | CLOSTRIDIUM DIFFICILE ANTIGENS - The present invention relates to recombinant | 2013-10-10 |
20130266584 | METHODS AND COMPOSITIONS FOR TREATING CELIAC DISEASE - The invention features the treatment of gastrointestinal disorders associated with an innate immune response tiggered by alpha amylase inhibitor CM3, alpha amylase inhibitor 0.19 (0.19), CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or alpha amylase inhibitor 0.53 (0.53). To this end, the invention features pharmaceutical compositions including neutralizing antibodies to CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53, food products containing reduced levels of CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 protein, the use of oral TLR4 inhibitors to block the effect of said alpha-amylase inhibitors, assays for identifying CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 content in food products, and assays for diagnosing subjects with a disorder related to CM3, 0.19, CM1, CM2, CMa, CMd, CM16, CMb, CMX1/CMX3, CMX2, and/or 0.53 triggered innate immune responses. | 2013-10-10 |
20130266585 | Method of Providing Disease-Specific Binding Molecules and Targets - Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described. | 2013-10-10 |
20130266586 | Method of Providing Disease-Specific Binding Molecules and Targets - Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described. | 2013-10-10 |
20130266587 | ANTIBODY SPECIFICALLY BINDING SYNOVIAL MICROVASCULATURE OF ARTHRITIS PATIENTS - The present invention provides an antigen binding polypeptide which specifically targets the synovial microvasculature of arthritis patients and comprises one or more complementarity determining regions (CDRs) selected from the group consisting of SEQ ID NOs 1 to 4. The present invention also relates to the use of such antigen binding polypeptides and conjugates thereof for use in the diagnosis and treatment of arthritis. | 2013-10-10 |
20130266588 | Agents, Compositions, And Methods For Treating Pruritis And Related Skin Conditions - This invention relates generally to a therapeutic use of TLR3 and TLR7 inhibitors to treat or reduce pruritus in a subject. | 2013-10-10 |
20130266589 | Biomarker for Alzheimer`s Disease or Mild Cognitive Impairment - Desmosterol alone, the combination of desmosterol and amyloid beta, the combination of desmosterol and gelsolin and the combination of desmosterol, amyloid beta and gelsolin can be used as in-blood biomarkers for Alzheimer's disease or mild cognitive impairment. A method for evaluating the effect of a candidate for a therapeutic agent to treat Alzheimer's disease or mild cognitive impairment, a method for aiding the diagnosis of Alzheimer's disease or mild cognitive impairment, and a method for diagnosing Alzheimer's disease or mild cognitive impairment are provided in which the biomarkers are used. | 2013-10-10 |
20130266590 | DIMERIC IAP INHIBITORS - The present invention provides compounds of formula M-L-M′ (where M and M′ are each independently a monomeric moiety of Formula (I), (II), (III) or (IV) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells. | 2013-10-10 |
20130266591 | USE OF TRI-SUBSTITUTED GLYCEROL COMPOUNDS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES - The present invention relates to the use of a tri-substituted glycerol compound for the manufacture of a medicament for the treatment of hematological malignancies. The invention also refers to a kit-of-parts comprising such a medicament. Finally, the invention also relates to a corresponding method for the treatment of such conditions as well as to an in vitro method for determining the susceptibility of such malignant cells to a medicament as defined in the invention. | 2013-10-10 |
20130266592 | COMPANION ANIMAL TREATMENTS - The invention relates to minimising the progression of cancer in a companion animal using P2X7 immunotherapy. | 2013-10-10 |
20130266593 | Microvesicle protein for cancer targeting - Microvesicles play essential roles in disease progression. The present invention provides a novel microvesicle membrane protein and application thereof. Disclosed is method comprises phosphorylated CSE1L (cellular apoptosis susceptibility protein)- or CSE1L-binging agents for microvesicle isolation, analysis, or binding for disease diagnosis or treatment. | 2013-10-10 |
20130266594 | ANTI-NOTCH1 ANTIBODIES - The present invention provides for antibodies that bind to Notch1. The present disclosure also provides methods of making the antibodies, pharmaceutical compositions comprising these antibodies and methods of treating disorders with the antibodies and pharmaceutical compositions. | 2013-10-10 |
20130266595 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF - A conjugate of formula (A): | 2013-10-10 |
20130266596 | NOVEL BENZODIAZEPINE DERIVATIVES - The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepines of formula (I) and (II), in which the diazepine ring (B) is fused with a heterocyclic ring (CD), wherein the heterocyclic ring is bicyclic or a compound of formula (III), in which the diazepine ring (B) is fused with a heterocyclic ring (C), wherein the heterocyclic ring is monocyclic. The invention provides cytotoxic dimers of these compounds. The invention also provides conjugates of the monomers and the dimers. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention. The invention further relates to methods of using the compounds or conjugates for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions. | 2013-10-10 |
20130266597 | Small Cationic Antimicrobial Peptides - The present invention relates generally to peptides and more specifically to antimicrobial and immunomodulatory host defense peptides. | 2013-10-10 |
20130266598 | Identification, Optimization And Use Of Cryptic HLA-B7 Epitopes For Immunotherapy - The invention provides methods for identifying a HLA-B*0702-restricted cryptic epitope in an antigen, as well as methods for increasing the immunogenicity of HLA-B*0702-restricted cryptic epitopes. The HLA-B*0702-restricted cryptic epitopes and their cognate immunogenic epitopes are useful for stimulating an immune reaction against the cryptic epitopes in a subject. Accordingly, the invention further provides pharmaceutical compositions comprising a HLA-B*0702-restricted cryptic epitope or a cognate immunogenic epitope thereof, and vaccination kits comprising such epitopes. The novel materials of the invention are particularly useful for efficiently treating patients having an HLA-B*0702 phenotype. | 2013-10-10 |
20130266599 | METHOD FOR INDUCING AN IMMUNE RESPONSE AGAINST AVIAN, SWINE, SPANISH, H1N1, H5N9 INFLUENZA VIRUSES AND FORMULATIONS THEREOF - A vaccine for immunization against Type A influenza virus is provided having an immunologically effective amount of peptide constructs obtained by linking together two or more peptides based on or derived from different molecules, and methods for producing the same. The peptide constructs have the formula P | 2013-10-10 |
20130266600 | Functional Mutations In Respiratory Syncytial Virus - The present invention provides recombinant respiratory syncytial viruses that have an attenuated phenotype and that comprise one or more mutations in the viral P, M2-1 and/or M2-2 proteins, as well as live attenuated vaccines comprising such viruses and nucleic acids encoding such viruses. Recombinant RSV P, M2-1 and M2-2 proteins are described. Methods of producing attenuated recombinant RSV, and methods of quantitating neutralizing antibodies that utilize recombinant viruses of family Paramyxoviridae, are also provided. | 2013-10-10 |
20130266601 | Mycoplasma Hyopneumoniae Vaccine - This invention provides an immunogenic composition including a soluble portion of a | 2013-10-10 |
20130266602 | PCV/Mycoplasma Hyopneumoniae Combination Vaccine - This invention provides a multivalent immunogenic composition including a soluble portion of a | 2013-10-10 |
20130266603 | PCV/Mycoplasma Hyopneumoniae/PRRS Combination Vaccine - This invention provides a trivalent immunogenic composition including a soluble portion of a | 2013-10-10 |
20130266604 | PEPTIDE CONTAINING MULTIPLE N-LINKED GLYCOSYLATION SEQUONS - Described herein is a peptide, referred to as a GlycoTag peptide, that includes repeats of an N-linked glycosylation sequon that is naturally present in | 2013-10-10 |
20130266605 | PEPTIDE INHIBITORS OF CD40L SIGNALING AND USES THEREFOR - The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signaling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-Cd40L costimulatory pathways. The invention also provides synthetic derivatives and analogs of the peptidyl inhibitors having enhanced binding affinity for CD40L or enhanced inhibitory activity relative to their parent molecules. | 2013-10-10 |
20130266606 | POLYVALENT CHIMERIC OSPC VACCINOGEN AND DIAGNOSTIC ANTIGEN - A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian | 2013-10-10 |
20130266607 | Cholera Toxin Chimera and its Use as a Staph Vaccine - The present invention relates to chimeric protein vaccines and methods of use thereof in the treatment of | 2013-10-10 |
20130266608 | METHODS AND COMPOSITIONS TO PRODUCE VACCINES AGAINST SMALLPOX IN PLANTS - Compositions and methods for producing plant-derived immunogenic compositions that confer immunity against smallpox in a subject are provided. Plants engineered to produce antigenic proteins as well as expression cassettes comprising nucleic acids encoding proteins thereof are described. Methods of immunizing subjects with plant-derived compositions are also provided. | 2013-10-10 |
20130266609 | VACCINE COMPOSITION - The present invention relates to DTP-based combination vaccine formulations, and concomitantly administered combination vaccine kits. Methods of administration of these vaccines and kits are also provided. | 2013-10-10 |
20130266610 | STIMULATING ANTI-TUMOR IMMUNE RESPONSE AND BOOSTING CANCER IMMUNOTHERAPY VIA EXPRESSION OF 15-PGDH - Disclosed herein are methods and materials for inhibiting tumor growth by administering viral vectors to tumor cells. Particularly exemplified herein are methods of inhibiting tumor growth of colon tumors by delivering 15-PGDH to tumor environment. Antigen presenting cells may be coadministered with 15-PGDH. | 2013-10-10 |
20130266611 | RECOMBINANT VIRAL VECTORS - The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention. | 2013-10-10 |
20130266612 | VACCINE COMPOSITION - An intraorally administrable vaccine composition useful to be a preventive or therapeutic agent for infectious diseases, and effectively induces a systemic immune response or a mucosal immune response is provided. A vaccine composition for administration to the oral cavity of a human or an animal, the vaccine composition containing at least one antigen derived from an infectious disease, and at least one selected from the group consisting of a toll-like receptor 4 (TLR4) agonist, a toll-like receptor 2/6 (TLR2/6) agonist, and cyclic dinucleotide, or a derivative or salt thereof. | 2013-10-10 |
20130266613 | OUTER MEMBRANE PROTEINS OF HISTOPHILUS SOMNI AND METHODS THEREOF - The present invention relates to immunological compositions of outer membrane proteins (OMPs) of | 2013-10-10 |
20130266614 | LIPID CARRIER FOR DELIVERY OF BIOACTIVE SUBSTANCE AND PHARMACEUTICAL COMPOSITION - The present invention provides a lipid carrier for delivering of a bioactive substance. The lipid carrier includes a lipid layer, a positive charged polymer and a surface active polymer. The positive charged polymer and the surface active polymer are respectively distributed on the lipid layer by non-covalent bonds. The present invention also provides a pharmaceutical composition. The present invention is advantageous for delivering bioactive substance efficiently. | 2013-10-10 |
20130266615 | NON-IMMUNOGENIC DELIVERY VEHICLE FOR BETA-, GAMMA-, AND DELTA-TOCOPHEROLS AND METHODS OF USING AND MAKING SAME - This disclosure provides microparticles for the delivery of non-immunogenic compositions providing delivery of β-, γ- and/or δ-tocopherols. | 2013-10-10 |
20130266616 | METHOD OF MANUFACTURING BONE GRAFT MATERIALS AND BONE GRAFT MATERIALS MANUFACTURED THEREBY - Bone graft materials include a bone-grafting material, which encourages regeneration of a missing bone tissue while being absorbed by the missing bone tissue, and a coating material, which is composed of at least one selected from the group consisting of magnesium, calcium hydroxyapatite, and mixtures thereof. | 2013-10-10 |
20130266617 | POLYMERIC MICELLES FOR POLYNUCLEOTIDE ENCAPSULATION - The present invention provides micelles having a polynucleotide encapsulated therein, the micelle comprising copolymers comprising hydrophobic moieties in a cationic complexing block. The invention further provides methods of preparing and using said micelles, and compositions thereof. | 2013-10-10 |
20130266618 | Dendritic Macroporous Hydrogels Prepared By Crystal Templating - The present invention includes a hydrogel and a method of making a porous hydrogel by preparing an aqueous mixture of an uncrosslinked polymer and a crystallizable molecule; casting the mixture into a vessel; allowing the cast mixture to dry to form an amorphous hydrogel film; seeding the cast mixture with a seed crystal of the crystallizable molecule; growing the crystallizable molecule into a crystal structure within the uncrosslinked polymer; crosslinking the polymer around the crystal structure under conditions in which the crystal structure within the crosslinked polymer is maintained; and dissolving the crystals within the crosslinked polymer to form the porous hydrogel. | 2013-10-10 |
20130266619 | Biocompatible Polyacrylate Compositions For Medical Applications - A composition comprising a structural component comprising linear acrylic homopolymers or linear acrylic copolymers and a biobeneficial component comprising copolymers having an acrylate moiety and a biobeneficial moiety is disclosed. A medical article comprising the composition in the coating thereof and a method of fabricating the medical article are also disclosed. | 2013-10-10 |
20130266620 | MEDICAL MATERIAL AND METHOD FOR MANUFACTURING SAME - The present invention aims to provide a medical material which is safe for the live body, has high biocompatibility and is useful for promotion of cell differentiation. The present invention produces a medical material for promoting cell differentiation, which contains polyamino acid as a main component, wherein the polyamino acid contains at least one kind of amino acid residue selected from the group consisting of an alanine residue, a valine residue, a leucine residue, an isoleucine residue, a phenylalanine residue, a glycine residue, a glutamine residue, an aspartic acid residue optionally containing a protecting group in the side chain, a tyrosine residue optionally containing a protecting group in the side chain, a tryptophan residue optionally containing a protecting group in the side chain, a lysine residue optionally containing a protecting group in the side chain, and a glutamic acid residue optionally containing a protecting group in the side chain. | 2013-10-10 |
20130266621 | STABLE COSMETIC PREPARATION WITH A HIGH PIGMENT CONTENT - A cosmetic preparation comprising ethylhexyl methoxycrylene and at least 20% by weight, based on the total weight of the preparation, of titanium dioxide and/or zinc oxide. | 2013-10-10 |
20130266622 | Personal Care Articles Comprising Substrates and Personal Care Compositions and Methods of Making the Same - A personal care article is disclosed having a substrate surrounding a personal care composition. Methods for making the personal care article and forming the personal care composition are also disclosed. | 2013-10-10 |
20130266623 | BLEACHING COMPOSITION COMPRISING MAGNESIUM SALT - The present invention relates to bleaching composition for keratin fibres, especially human hair, comprising at least one compound with bleaching and/or highlighting effect and a magnesium salt. Further object of the present invention is the use of at least one magnesium salt in a bleaching and/or highlighting composition for keratin fibres, especially for human hair, comprising at least one compound with bleaching and/or highlighting effect for preventing temperature increase going above 50° C., preferably above 45° C. and more preferably above 40° C. in a period of at least 60 min after mixing water free bleaching and/or highlighting composition and oxidizing lotion. | 2013-10-10 |
20130266624 | WIPE FOR APPLICATION OF AT LEAST ONE ACTIVE PRINCIPLE ON THE SKIN - Dry wipe for application of at least one active principle on the skin, including: an inert laminar support; a plurality of microcapsules applied to the inert laminar support, the microcapsules containing at least one active principle; at least one surfactant applied to the inert laminar support. | 2013-10-10 |
20130266625 | NANOPARTICLES BASED ON POLY (LACTIC GLYCOLIC) ACID FOR COSMETIC APPLICATIONS - On one hand, the present invention relates to cosmetic compositions comprising poly(lactic glycolic)acid (PLGA) nanoparticles for applications to the skin. On the other hand, it also concerns polymeric nanoparticles having on its surface a plurality of cosmetically active agents, each of said agents being associated to said nanoparticle via oleylcysteineamide, delivery systems for topical application based on said particles and cosmetic formulations comprising said particles. | 2013-10-10 |
20130266626 | ACTIVE AND INTELLIGENT ADDITIVE, POLYMER AND ARTICLE - The present invention relates to active and intelligent additives having hybrid characteristics, that are compatible with polymers, are thermally and mechanically stable, are capable of releasing electrons and/or photons in the presence of chemical compounds, specifically amino compounds, amide compounds, oxygen reducing compounds, water or vapors thereof. The active and intelligent additives incorporate themselves into polymer matrices allowing the obtainment of active and intelligent polymeric articles. These active and intelligent polymeric articles may act as inhibitors of growth of microorganisms and fungi, as well as indicators of the presence of gasses, either in the atmosphere or caused by the decomposition of foodstuffs, for example. | 2013-10-10 |
20130266627 | Method for Treating Mammals for Uterine Disorders with Therapeutic Nanolipidic Vehicles - A composition for intrauterine lavage comprising phenolic compounds encapsulated within a potentiated nanolipidic process is disclosed. The encapsulated nanolipidic preparation is preferably provided as a concentrated solution. Said concentrated solution is mixed with a sterile diluent suitable for the intrauterine environment, and said diluted nanolipidic preparation is used to lavage the uterus of a mammal in need of treatment of one or more conditions of the uterus and/or to maintain general uterine health. Preferably, the encapsulated phenolic compounds are extracted from | 2013-10-10 |
20130266628 | GRAPHENE-BASED ANTIMICROBIAL COMPOSITES - Composite materials comprising functionalized graphenes, methods of preparing the composite materials, and methods of using the composite materials are described herein. A composite material comprising reduced graphene oxide, chitosan, and native lactoferrin show much higher antimicrobial activity versus individual reduced graphene oxide, chitosan, and native lactoferrin alone. | 2013-10-10 |
20130266629 | MEDICAL DEVICE HAVING A SURFACE COMPRISING ANTIMICROBIAL METAL - A medical device intended for contact with living tissue comprises a substrate having a surface, which surface comprises a layer comprising one or more compound(s)) of at least one non-toxic post-transition metal, such as a gallium or bismuth compound. A layer comprising a compound of a non-toxic post-transition metal has been shown to inhibit biofilm formation on the surface of the medical device, which may reduce the risk for infection e.g. around a dental implant. A method of producing the medical device comprises: a) providing a substrate having a surface; and applying a compound of a non-toxic post-transition metal onto said surface to form a layer, e.g. using a thin film deposition technique. | 2013-10-10 |
20130266630 | COMPOSITION FOR INTRAOCULAR IMPLANTATION OF BEVACIZUMAB - A solid, compressed pharmaceutical composition comprises i) a peptide active pharmaceutical ingredient, ii) a polysaccharide excipient and/or an albumin, and iii) an oligosaccharide excipient. The polysaccharide excipient may be hyaluronic acid, or the potassium salt thereof, and the oligosaccharide excipient may be trehalose. | 2013-10-10 |
20130266631 | CLONIDINE COMPOUNDS IN A BIODEGRADABLE MATRIX - Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine in a matrix at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate matrix formulations are provided within biodegradable polymers, this pain relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days. | 2013-10-10 |
20130266632 | DRUG DELIVERY SYSTEM BASED ON POLYETHYLENE VINYLACETATE COPOLYMERS - A drug delivery system consisting of one or more compartments and comprising a progestogenic compound dissolved in a thermoplastic polyethylene vinylacetate copolymer whereby,
| 2013-10-10 |
20130266633 | Transdermal Therapeutic System - The present invention relates to Transdermal Therapeutic Systems having a silicone adhesive layer, to Transdermal Therapeutic Systems providing specific plasma concentrations, to their manufacture and use. | 2013-10-10 |
20130266634 | BIOACTIVE FUS1 PEPTIDES AND NANOPARTICLE-POLYPEPTIDE COMPLEXES - A nanoparticle-polypeptide complex comprising a bioactive polypeptide in association with a nanoparticle, wherein the bioactive polypeptide is modified by the addition of a chemical moiety that facilitates cellular uptake of the protein. The polypeptide can be a protein or a peptide. In some embodiments, the amino acid sequence of the protein or peptide is derived from the amino acid sequence of a tumor suppressor gene product. | 2013-10-10 |
20130266635 | PHOSPHOLIPID DRUG ANALOGS - Provided in some embodiments are compositions comprising a compound having a structure according to Formula A or Formula B: | 2013-10-10 |
20130266636 | METHODS FOR BLOCKING CELL PROLIFERATION AND TREATING DISEASES AND CONDITIONS RESPONSIVE TO CELL GROWTH INHIBITION - In alternative embodiments, the invention provides methods for regulating or modulating RAF kinases. In alternative embodiments, the invention provides methods for ameliorating, preventing and/or treating diseases, infections and/or conditions having unwanted, pathological or aberrant cell proliferation, or that are responsive to inhibition or arrest of cell growth, by administration of an allosteric RAF inhibitor and/or any agent which prevents localization of RAF to mitotic spindles or mid-bodies. | 2013-10-10 |
20130266637 | COMPOSITION FOR TREATING CANCER BY THE CONTROLLED RELEASE OF AN ACTIVE SUBSTANCE - The invention relates to a novel composition for treating cancer, which allows the active substance to be released in the direct presence of the cells which are to be treated with the active substance. Said composition comprises an active substance carrier which is in the form of a liposome comprising a disulfide group, a cytostatic agent being contained in the active substance carrier. The invention also relates to a method for the locally defined release of a cytostatic agent. | 2013-10-10 |
20130266638 | NATURAL PRODUCT INHIBITORS OF 3DG - Compositions are disclosed which have as a component thereof an inhibitor of the enzymatic production of 3-deoxyglucosone (3DG) from fructoselysine and/or an inactivator of 3DG, and which are useful for the treatment or prophylaxis of a condition or disease state that is alleviated by inhibiting such 3DG production. Methods of using such compositions, e.g., for improving the appearance, texture and/or elasticity of aging skin, are also disclosed. | 2013-10-10 |
20130266639 | METHODS FOR TREATING TRIPLE NEGATIVE BREAST CANCER USING BIFUNCTIONAL SRC 3 shRNA - The present invention includes compositions and methods treating triple negative breast cancer comprising administering a therapeutically effective amount of a formulation that includes vector that expresses an SRC-1-specific bifunctional shRNA, an SRC-3-specific bifunctional shRNA, or both, to impair triple negative breast cancer cell growth. | 2013-10-10 |
20130266640 | MODIFIED NUCLEOSIDE, NUCLEOTIDE, AND NUCLEIC ACID COMPOSITIONS - The present disclosure provides, inter alia, formulation compositions comprising modified nucleic acid molecules which may encode a protein, a protein precursor, or a partially or fully processed form of the protein or a protein precursor. The formulation composition may further include a modified nucleic acid molecule and a delivery agent. The present invention further provides nucleic acids useful for encoding polypeptides capable of modulating a cell's function and/or activity. | 2013-10-10 |
20130266641 | CARRIER FOR NEGATIVELY CHARGED DRUGS COMPRISING A CATIONIC LIPID AND A PREPARATION METHOD THEREOF - Disclosed are a carrier for delivering a negatively charged drug, comprising a cationic lipid represented by formula 1, and a preparation method thereof. Also disclosed is a pharmaceutical composition comprising a negatively charged drug and a cationic lipid represented by formula 1, wherein the negatively charged drug forms a complex with the cationic lipid. The composition can increase the in vivo stability of the negatively charged drug after local or systemic administration and allows the intracellular delivery of the negatively charged drug. Thus, the composition will be useful for improving the therapeutic effect of the negatively charged drug. | 2013-10-10 |
20130266642 | MALODOR REDUCTION COMPOSITIONS - The present invention relates to unscented and low scented malodor reduction compositions and methods of making and using same. The malodor reduction compositions are suitable for use in a variety of applications, including use in consumer products, for example, air freshening compositions, laundry detergents, fabric enhancers, surface cleaners, beauty care products, dish care products, diapers, feminine protection articles, and plastic films for garbage bags. | 2013-10-10 |
20130266643 | Compositions comprising glyceryl-triacetate (GTA) and uses in human performance optimization and thermogenesis - Described herein are compositions comprising glyceryl-triacetate (GTA) for use in delivering non-glucose energy deriving metabolites during physical performance, which reduce lactate production and serve as thermogenic agents. | 2013-10-10 |
20130266644 | SENSOR - The present invention relates to a scaffolded sensor with a container comprising a drug for triggering drug release, wherein the scaffold is intrinsically conformationally metastable and a method to its manufacture. | 2013-10-10 |
20130266645 | DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN ANTIPARASITIC ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL ACTION - The present invention relates to compounds derived from steroids of the general formula (I) | 2013-10-10 |
20130266646 | PHARMACEUTICAL FORMULATIONS COMPRISING CCR3 ANTAGONISTS - The present invention relates to pharmaceutical compositions containing one or more compounds of formula 1 | 2013-10-10 |
20130266647 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE - A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a thiazolidinedione derivative is herein disclosed and described. | 2013-10-10 |
20130266648 | TABLETED COMPOSITIONS CONTAINING ATAZANAVIR - Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating HIV. | 2013-10-10 |
20130266649 | NOVEL PHARMACEUTICAL COMPOSITION - Disclosed are novel pharmaceutical compositions containing N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide dimethyl sulfoxide solvate, methods of using the compositions in therapy and processes for preparing the same. | 2013-10-10 |
20130266650 | BUPROPION HYDROBROMIDE AND THERAPEUTIC APPLICATIONS - Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described. | 2013-10-10 |
20130266651 | LONG ACTING DUAL RELEASE PRODUCT CONTAINING CARBINOXAMINE AND PSEUDOEPHEDRINE - Provided are oral dosage forms that contain carbinoxamine in an immediate release format, and pseudoephedrine in a prolonged release format. The biphasic oral dosage forms may also contain other active ingredients in combination with carbinoxamine, including other decongestants, antitussives, analgesics and expectorants. | 2013-10-10 |
20130266652 | LIQUID PHARMACEUTICAL COMPOSITION FOR THE DELIVERY OF ACTIVE INGREDIENTS - The invention provides novel pharmaceutical compositions based on semifluorinated alkanes which are useful as carriers for a broad range of active ingredients. Preferred active ingredients include poorly water-soluble and/or hydrolytically sensitive drug substances. The compositions are designed as suspensions and have superior physical properties which make them highly useful as pharmaceutical delivery systems. The compositions may be administered topically into the eye, or injected via the subcutaneous or intramuscular route. The invention further provides kits comprising such compositions. | 2013-10-10 |